InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,289.88
(
0.31%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: BTH post# 1367

Wednesday, 08/18/2010 7:57:44 PM

Wednesday, August 18, 2010 7:57:44 PM

Post# of 80490
You asked

What percent of patients on Gleevec develop a mutation or resistance? 10%? Less than 10%?

Answer: More than 10%

Eventually, 30% of pts become resistant to gleevec(about half from mutations) and 50% become resistant to sprycel and/or tasigna.

It's a significant market whether AP534 eventually gets approved as first line treatment or not.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up